Skip To Main Content
Sandra D. Isidean on Muck Rack

Sandra D. Isidean

As seen in: Color Research & Application, Nature, Cancer Epidemiology, Biomarkers & Prevention
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Sandra D. Isidean’s profile

Articles by Sandra D. Isidean

A phase 2, randomised, placebo-controlled study to evaluate once-daily oral Travelan for the prevention of Travellers’ diarrhoea

|
By Joanne Casey, Frederic Poly, Chad K. Porter, Dilara Islam, Renee M Laird, Sandra D. Isidean, Kayla J Testa, Vicky Chapman, Anya E. Shindler, Ashley Franks, Sharon M Tennant, Wilbur H. Chen, Mohamed Al-Ibrahim, Kaelyn Lamberti, Charmagne Beckett, Jerry Kanellos
| Nature Verified
Abstract This study evaluated once-daily oral dosing of Travelan (IMM-124E), a bovine polyclonal antibody product, for prevention of Enterotoxigenic Escherichia coli (ETEC)-induced diarrhoea. In this randomised, double-blind, placebo-controlled trial using an ETEC-controlled human infection model, 60 healthy subjects received 1200mg Travelan or placebo once-daily for 7 days. Two days after dosing commenced, subjects were challenged with ETEC strain H10407 and monitored for diarrhoeal symptoms.
Open in Who Shared Issue with article?

Clinical performance of the BD Onclarity extended genotyping assay for the management of women positive for human papillomavirus in cervical cancer screening

|
By Karena D. Volesky, Marie-Hélène Mayrand, Sandra D. Isidean, Sindy Magnan
| Cancer Epidemiology, Biomarkers & Prevention
Research Article Karena D Volesky, Sindy Magnan, Marie-Hélène Mayrand, Sandra D Isidean, Mariam El-Zein, Emilie Comète, Eduardo L Franco and François Coutlée DOI: 10.1158/1055-9965.EPI-21-1082 Abstract Background: Among women whose cervical specimens tested positive for high-risk human papillomaviruses (hrHPV) via the Hybrid Capture 2 assay in the Canadian Cervical Cancer Screening Trial (CCCaST), we assessed hrHPV genotype concordance between BD OnclarityTM HPV Assay and Roche's Linear...
Open in Who Shared Issue with article?

Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening

|
By Joseph E. Tota, Sandra D. Isidean, Eduardo Franco
| Color Research & Application Verified
Abstract The performance of cervical cancer screening will decline as a function of lower disease prevalence—a consequence of successful human papillomavirus (HPV) vaccination. Replacement of cytology with molecular HPV testing as the primary screening test and adoption of risk-based screening, with less intense screening of vaccinated individuals and initiated at older ages is expected to improve efficiency.
Open in Who Shared Issue with article?
Show More